Gleneagle Gold Ltd (ASX:GLN) continues to advance towards re-listing on the ASX as a medical cannabis company.
The company is now undertaking a consolidation of 5 shares into 1, which will reduce the total number of shares on issue to 120.6 million.
The company will host its general meeting on the 25th July 2016 in Perth, where shareholders will vote on the significant change to the nature and scale of its activities.
Gleneagle is in the final steps of the reverse takeover of Zelda Therapeutics, a California-based biotechnology company.
Zelda is a biotechnology company that was spun out of a successful US-based medicinal cannabis group - Aunt Zelda’s - that has treated hundreds of patients in California.
Zelda has exclusive, global access to an extensive set of human data related to medicinal cannabis-based formulations and treatment protocols.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.